X0306 4 2014-02-21 1 0001375200 NUPATHE INC. PATH 0001260426 FEDERICI WILLIAM J C/O NUPATHE INC., 7 GREAT VALLEY PARKWAY, SUITE 300 MALVERN PA 19355 1 0 0 0 Common Stock 2014-02-21 4 D 0 13500 6.80 D 0 D Stock option (right to buy) 9.00 2014-02-21 4 D 0 7486 0.00 D 2021-01-05 Common Stock 7486 0 D Stock option (right to buy) 7.75 2014-02-21 4 D 0 6014 0.00 D 2021-03-03 Common Stock 6014 0 D Stock option (right to buy) 7.66 2014-02-21 4 D 0 6750 0.00 D 2021-06-08 Common Stock 6750 0 D Stock option (right to buy) 3.70 2014-02-21 4 D 0 2802 3.10 D 2022-03-31 Common Stock 2802 0 D Stock option (right to buy) 3.37 2014-02-21 4 D 0 6750 3.43 D 2022-06-07 Common Stock 6750 0 D Stock option (right to buy) 4.03 2014-02-21 4 D 0 2436 2.77 D 2022-06-30 Common Stock 2436 0 D Stock option (right to buy) 3.56 2014-02-21 4 D 0 2791 3.24 D 2022-09-30 Common Stock 2791 0 D Stock option (right to buy) 3.38 2014-02-21 4 D 0 2916 3.42 D 2022-12-31 Common Stock 2916 0 D Stock option (right to buy) 3.45 2014-02-21 4 D 0 2157 3.35 D 2023-03-31 Common Stock 2157 0 D Stock option (right to buy) 2.99 2014-02-21 4 D 0 13500 3.81 D 2023-06-05 Common Stock 13500 0 D Stock option (right to buy) 3.06 2014-02-21 4 D 0 3063 3.74 D 2023-06-30 Common Stock 3063 0 D Stock option (right to buy) 2.41 2014-02-21 4 D 0 4795 4.39 D 2023-09-30 Common Stock 4795 0 D Stock option (right to buy) 3.27 2014-02-21 4 D 0 3538 3.53 D 2023-12-31 Common Stock 3538 0 D Includes all restricted stock units that became fully vested upon the consummation of the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated January 17, 2014, among the issuer, Teva Pharmaceutical Industries Ltd. and Train Merger Sub, Inc.(the "Merger Agreement"). Disposed upon the Merger, in exchange for $3.65 per share, plus contractual rights to receive up to an additional $3.15 in contingent cash consideration payments per share. Pursuant to the Merger Agreement, all options became fully vested upon the consummation of the Merger. Pursuant to the Merger Agremeent, the option was converted into the right to receive, at the earliest date at which the sum of (1) the $3.65 per share cash portion of the merger consideration and (2) the amount per share in cash previously paid or to be paid at such date in connection with the Contingent Cash Consideration Agreement entered into in connection with the Merger Agreement (such sum, the "Per Share Paid Value") exceeds the per-share exercise price under the option: (x) an amount in cash equal to the number of shares of common stock subject to the option multiplied by the excess of (i) the then applicable Per Share Paid Value over (ii) the per-share exercise price under the option; and (y) the right to receive, in respect of each share of common stock subject to the option, each contingent cash consideration payment that, as of such date, has not yet become payable. /s/ Michael F. Marino, attorney-in-fact 2014-02-25